Printer Friendly

OncoSenX Raises USD 3m to Advance New Class of Cancer Therapeutics.

M2 PHARMA-July 11, 2019-OncoSenX Raises USD 3m to Advance New Class of Cancer Therapeutics

(C)2019 M2 COMMUNICATIONS

- US-based oncology company OncoSenX, Inc., a late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, has raised USD 3m in pre-seed funding to advance its pipeline, the company said.

"These funds will allow us to accelerate the preclinical research necessary for us to begin phase 1 clinical development," said Matthew Scholz, chief executive officer of OncoSenX. "We believe our non-viral gene therapy for solid tumors represents the first in a new class of cancer therapeutics. The OncoSenX team is diligently working to bring this new approach into the clinic for the benefit of a global oncology community clearly in need of new options."

OncoSenX is developing a highly selective tumor-killing platform with two main components: a proprietary lipid nanoparticle for cellular delivery and a highly selective DNA payload.

The LNP is designed to deliver its non-integrating DNA payload to solid tumors, while an engineered promoter drives expression of a potent, inducible death protein only in the target cell population. The goal is to precisely target cell populations based on their genetic activity without harming nearby cells.

This platform can be effectively programmed to implement logic gates (IF/OR/AND) to provide selectivity to any target cell based on its genetics.

OncoSenX is currently preparing for its regulatory interactions and will then perform pivotal toxicology studies in anticipation of filing to begin human trials.

OncoSenX is a late preclinical-stage oncology company developing therapeutics to kill cancer cells based on their genetics. Headquartered in Seattle, Washington, the company's technology platform targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA approach.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 11, 2019
Words:297
Previous Article:Savonix Publishes Paper in Cognition, Brain, Behavior.
Next Article:Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |